Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 15/20 | 1.00 |
| ▸ | NFKBIA | P25963 | 8/20 | 1.00 |
| ▸ | RELA | Q04206 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | MDM4 | O15151 | 1/20 | 1.00 |
| ▸ | MDM2 | Q00987 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.73 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.60 |
| ▸ | G6PD | P11413 | 1/20 | 0.60 |
| ▸ | METAP2 | P50579 | 1/20 | 0.60 |
| ▸ | METAP1 | P53582 | 1/20 | 0.60 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11973449 | 0.86 | SLC40A1 (0.76) | SLC40A1NFKBIARELATDP1MEN1 | |
| SCHEMBL11973142 | 0.86 | SLC40A1 (0.75) | SLC40A1NFKBIARELATDP1MEN1 | |
| SCHEMBL11973210 | 0.86 | NFKBIA (0.85) | SLC40A1NFKBIARELATDP1MEN1 | |
| SCHEMBL11973444 | 0.86 | SLC40A1 (0.85) | SLC40A1NFKBIARELATDP1MEN1 | |
| SCHEMBL11973610 | 0.85 | NFKBIA (0.74) | SLC40A1NFKBIARELATDP1MEN1 | |
| SCHEMBL11973667 | 0.85 | RELA (1.00) | SLC40A1NFKBIARELATDP1MEN1 | |
| SCHEMBL11973893 | 0.85 | SLC40A1 (1.00) | SLC40A1NFKBIARELATDP1MEN1 | |
| SCHEMBL11972893 | 0.85 | SLC40A1 (0.77) | SLC40A1NFKBIARELATDP1MEN1 | |
| SCHEMBL11973811 | 0.84 | RELA (0.80) | SLC40A1NFKBIARELATDP1MEN1 | |
| SCHEMBL11972968 | 0.83 | SLC40A1 (0.86) | SLC40A1NFKBIARELATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | OTAGO INNOVATION LIMITED (NZ) | 2023-07-04 | — | — | US | disclosed |
| US-11413278-B2 | Compounds and methods for promoting stress resistance | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-16 | — | — | US | disclosed |
| US-11213701-B2 | Neuroprotective quinoline sulfonamides | DAHL RUSSELL (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200188706-A1 | NEUROPROTECTIVE QUINOLINE SULFONAMIDES | DAHL RUSSELL (US) | 2020-06-18 | — | — | US | disclosed |
| CN-103492028-B | Sulfonaminoquinoline hepcidin antagonists | 维福（国际）股份公司 | 2017-02-08 | — | — | CN | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885NFKBIA 277/4885RELA 1102/4885 |
| US-20200188706-A1 | NEUROPROTECTIVE QUINOLINE SULFONAMIDES | SUMO3, SUMO2, PSEN1 | SLC40A1 4609/4885NFKBIA 1157/4885RELA 126/4885 |
| US-11213701-B2 | Neuroprotective quinoline sulfonamides | SUMO3, SUMO2, PSEN1 | SLC40A1 4609/4885NFKBIA 1157/4885RELA 126/4885 |
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | NQO2, SDHA, SIRT5 | SLC40A1 4081/4885NFKBIA 998/4885RELA 376/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885NFKBIA 277/4885RELA 1102/4885 |
| US-11413278-B2 | Compounds and methods for promoting stress resistance | HSPA9, ATF4, GPX4 | SLC40A1 1579/4885NFKBIA 399/4885RELA 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.